Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE-AT: Tirzepatide vs Semaglutide in Obesity and Metabolic Syndrome
NCT07589322Recruiting
- Sponsor
- Tri-Service General Hospital
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tirzepatide in obesity and metabolic syndrome (2 arms), sponsored by Tri-Service General Hospital. Primary endpoints: Percent change in total body weight at 6 months, Total fat to lean mass loss ratio at 6 months and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT07589322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589322.